While most anticancer agents are small molecular weight compounds that inhibit specific steps in the pathways contributing to cancer growth, or monoclonal antibodies that target specific antigens hyper-expressed in cancer cells, recent efforts have also been directed towards bacterial pathogens that are known to allow cancer regression. Consequently, patents that cover the construction or characterization of specific bacteria, with or without additional cloned genes, are available. This review is, however, focused on patents that claim bacterial proteins as potential anticancer agents. In particular, we describe two bacterial proteins that demonstrate both anticancer and antiviral, and often antiparasitic, activities, and therefore the patents cover multiple aspects of the potential use of such bacterial proteins in the treatment of not only cancer but also malaria or other parasitic diseases and HIV/AIDS and similar viral diseases. We also briefly discuss patents that cover the use of CpG-rich DNA, including bacterial DNA, as potential anticancer agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/157489207782497163 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Screening of high glucose tolerant Escherichia coli for L-valine fermentation by autonomous evolutionary mutation.
Appl Microbiol Biotechnol
January 2025
College of Marine and Bioengineering, Yancheng Institute of Technology, Yancheng, 224051, PR China.
L-valine holds wide-ranging applications in medicine, food, feed, and various industrial sectors. Escherichia coli, a pivotal strain in industrial L-valine production, features a concise fermentation period and a well-defined genetic background. This study focuses on mismatch repair genes (mutH, mutL, mutS, and recG) and genes associated with mutagenesis (dinB, rpoS, rpoD, and recA), employing a high-glucose adaptive culture in conjunction with metabolic modifications to systematically screen for superior phenotypes.
View Article and Find Full Text PDFThe PurR family transcriptional regulator promotes butenyl-spinosyn production in Saccharopolyspora pogona.
Appl Microbiol Biotechnol
January 2025
Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology, Institute of Biochemical Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing, 100081, China.
Butenyl-spinosyn, derived from Saccharopolyspora pogona, is a broad-spectrum and effective bioinsecticide. However, the regulatory mechanism affecting butenyl-spinosyn synthesis has not been fully elucidated, which hindered the improvement of production. Here, a high-production strain S.
View Article and Find Full Text PDFXopAE Effector from pv. Targets HSP20-Like p23 Cochaperone to Suppress Plant Basal Immunity.
Mol Plant Microbe Interact
January 2025
Universidad de los Andes, Biology, Cra 1 # 18A-10, Bogota, Cundinamarca, Colombia, 110121;
Pathogenic bacteria use Type 3 effector proteins to manipulate host defenses and alter metabolism to favor their survival and spread. The non-model bacterial pathogen pv. () causes devastating disease in cassava.
View Article and Find Full Text PDFFhaA plays a key role in mycobacterial polar elongation and asymmetric growth.
mBio
January 2025
Analytical Biochemistry and Proteomics Unit, Instituto de Investigaciones Biológicas Clemente Estable and Institut Pasteur de Montevideo, Montevideo, Uruguay.
Unlabelled: Mycobacteria, including pathogens like , exhibit unique growth patterns and cell envelope structures that challenge our understanding of bacterial physiology. This study sheds light on FhaA, a conserved protein in , revealing its pivotal role in coordinating cell envelope biogenesis and asymmetric growth. The elucidation of the FhaA interactome in living mycobacterial cells reveals its participation in the protein network orchestrating cell envelope biogenesis and cell elongation/division.
View Article and Find Full Text PDFSynthesis of new dihydropyrimidine derivatives and investigation of their antimicrobial and DNA gyrase inhibitory activities.
Arch Pharm (Weinheim)
January 2025
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.
Quinolone antibiotics are known for their antibacterial activity by inhibiting the enzyme DNA gyrase. Inspired by their mechanism, new compounds combining 1,4-dihydropyrimidine, a quinolone isostere, with pyridine/pyrimidine rings were synthesized. These derivatives showed antibacterial effects, likely through DNA gyrase inhibition, as supported by molecular docking and dynamics simulations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!